Coherus Announces U.S. Launch of LOQTORZI™
January 02, 2024 08:29 ET
|
Coherus BioSciences, Inc.
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients...
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
October 27, 2023 15:07 ET
|
Coherus BioSciences, Inc.
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023 09:00 ET
|
Coherus BioSciences, Inc.
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments - - Many...
Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report
September 07, 2023 17:49 ET
|
Novotech
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –...
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
Global Market for Nasopharyngeal Carcinoma Treatment is expected to rise at a CAGR of 5.9% to hit a revenue of US$ 2.1 Billion | Future Market Insights, Inc.
May 04, 2023 21:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, May 04, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Nasopharyngeal carcinoma treatment market is expected to grow at a value of 5.9% CAGR, according to Future...
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023 08:05 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Global Nasopharyngeal Carcinoma Market Size To Grow At a CAGR of 5.6% From 2022 To 2030
March 30, 2023 14:30 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , March 30, 2023 (GLOBE NEWSWIRE) -- The Global Nasopharyngeal Carcinoma Market Size is projected to reach multimillion USD by 2030, in comparison to 2021, at a CAGR of 5.6%...
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
May 02, 2022 07:00 ET
|
Coherus BioSciences, Inc.
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
September 01, 2021 08:01 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc....